Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.20 USD

51.20
2,122,230

+0.77 (1.53%)

Updated Jul 24, 2024 04:00 PM ET

Pre-Market: $52.70 +1.50 (2.93%) 8:56 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 20% (201 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

SNY or LLY: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SNY vs. LLY: Which Stock Is the Better Value Option?

Pfizer's (PFE) Hemophilia B Gene Therapy Meets Study Goal

by Zacks Equity Research

Data from a late-stage study shows that treatment with Pfizer's (PFE) hemophilia B gene therapy resulted in a 71% reduction in annualized bleed rate (ABR) compared to standard-of-care treatment.

TG Therapeutics (TGTX) Gets FDA Nod for Multiple Sclerosis Drug

by Zacks Equity Research

The FDA approves TG Therapeutics' (TGTX) Briumvi (ublituximab-xiiy) for treating relapsing forms of multiple sclerosis. The company plans to launch the drug in the first quarter of 2023. Stock up.

Pfizer (PFE) Pentavalent Meningitis Jab BLA Gets FDA Acceptance

by Zacks Equity Research

The FDA assigns a standard review to Pfizer's (PFE) BLA for pentavalent meningococcal vaccine candidate (MenABCWY), with a decision expected in October 2023.

Zymeworks (ZYME) Stock Up 29% in Three Months: Here's Why

by Zacks Equity Research

Zymeworks (ZYME) recently entered a collaboration with Jazz Pharmaceuticals (JAZZ) for its lead pipeline candidate. This has been a significant catalyst for the stock.

Kinjel Shah headshot

3 Big Drug, Biotech Stocks to Boost Your Portfolio in 2023

by Kinjel Shah

Here we discuss three big drug and biotech companies, Sanofi (SNY), GSK (GSK) and BioNTech (BNTX), which may prove to be good bets for your portfolio next year.

Sanofi's (SNY) Dupixent & Vaccines Make the Stock Attractive

by Zacks Equity Research

One can invest in Sanofi (SNY) due to the strong performance of Dupixent, above-market sales growth of the Consumer unit, consistent pipeline innovation and regular accretive collaboration deals.

Merck (MRK) Inks Deal to Develop Antibodies for Treating Cancer

by Zacks Equity Research

Merck (MRK) partners with Kelun-Biotech to develop seven antibody-drug conjugates targeting cancer indications. Merck will have an exclusive license to develop and commercialize these candidates.

Pfizer's (PFE) Etrasimod Filings Receive Review Acceptance

by Zacks Equity Research

The regulatory filings seek approval for Pfizer's (PFE) etrasimod in UC indication. A final decision in the U.S. is expected in 2023, while the decision in the EU is expected in 2024.

Roche (RHHBY) Actemra Gets FDA Nod for Adults With COVID-19

by Zacks Equity Research

Roche (RHHBY) obtains FDA approval for Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients. The drug was earlier granted an EUA.

Merck (MRK), Seagen Keytruda-Padcev sBLAs Get FDA Priority Tag

by Zacks Equity Research

Merck (MRK) and Seagen's (SGEN) sBLAs seek approval of Padcev plus Keytruda for locally advanced or metastatic urothelial cancer in patients who are not eligible for cisplatin-containing chemotherapy.

AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs

by Zacks Equity Research

The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.

AstraZeneca (AZN) Gets EU Nod & CHMP Opinions for Some Drugs

by Zacks Equity Research

The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.

Sanofi (SNY) Dupixent Gets CHMP Nod to Eosinophilic Esophagitis

by Zacks Equity Research

The CHMP recommends approval of Sanofi (SNY) and partner Regeneron's Dupixent for the treatment of adults and adolescents with eosinophilic esophagitis.

Roche's (RHHBY) Hemophilia A Drug Gets Positive CHMP Opinion

by Zacks Equity Research

Roche (RHHBY) receives a positive CHMP recommendation for label expansion of the hemophilia A drug Hemlibra in the European Union (EU).

AbbVie (ABBV) Vraylar Gets FDA Nod for Major Depressive Disorder

by Zacks Equity Research

FDA approves AbbVie's (ABBV) Vraylar (cariprazine) for its fourth indication - the adjunctive treatment of patients with MDD.

Kinjel Shah headshot

Pharma Stock Roundup: LLY's 2023 View, MRK-MRNA Joint Cancer Vaccine Data & More

by Kinjel Shah

Eli Lilly (LLY) gives its financial guidance for 2023. Merck (MRK) and Moderna's (MRNA) mRNA-based cancer vaccine shows positive results in a joint study.

Kymera (KYMR) Up on Positive Data From Phase I Study on KT-474

by Zacks Equity Research

Kymera (KYMR) posts positive data from a phase I study on KT-474 for treating patients with hidradenitis suppurativa and atopic dermatitis. Sanofi to advance KT-474 in phase II study.

Sanofi's (SNY) Dupixent Gets Europe Nod for Prurigo Nodularis

by Zacks Equity Research

The EC approves Sanofi (SNY) and its partner Regeneron's Dupixent for the treatment of adult patients with prurigo nodularis.

Debdutta Sinha headshot

5 Momentum Stock Bargains Hunters Would Love Chasing

by Debdutta Sinha

Given the prevailing challenges in the market, investors can consider momentum stocks like SNY, GSK, ULTA, UAL and UTHR to get handsome returns in the near term.

What Makes Sanofi (SNY) a New Buy Stock

by Zacks Equity Research

Sanofi (SNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SNY vs. LLY: Which Stock Is the Better Value Option?

by Zacks Equity Research

SNY vs. LLY: Which Stock Is the Better Value Option?

Amgen (AMGN) to Buy Horizon Therapeutics For $27.8 Billion

by Zacks Equity Research

Amgen (AMGN) wins the race to buy Horizon Therapeutics and makes an acquisition offer of $27.8 billion.

Kinjel Shah headshot

Pharma Stock Roundup: SNY, GSK, PFE Relieved on Zantac Win & Other Updates

by Kinjel Shah

A U.S. district court dismisses thousands of lawsuits involving Zantac, which spells relief for GSK (GSK), Sanofi (SNY) and Pfizer (PFE). Pfizer and AbbVie (ABBV) announce new research collaborations.